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ABSTRACT  
 
Introduction and Aims: Street-involved youth are known to be at elevated risk of 
initiating injection drug use. However, the impact of so-called “gateway” drugs, such as 
cannabis, on injection initiation is unknown. The objective of this study was to examine 
the association between cannabis use and initiation of injection drug use among a 
prospective cohort of street-involved youth in Vancouver, Canada. 
 
Design and Methods: Data for this study were collected from the At-Risk Youth Study 
(ARYS). From September 2005 to May 2015, participants aged 14-26 who reported illicit 
drug use were recruited into this open prospective cohort study. An extended Cox 
regression model with time-updated covariates was used to identify factors 
independently associated with injection initiation.  
 
Results: During the study period 481 street-involved youth were included in this study. 
Of these, 228 (47.4%) reported at least daily cannabis use, and 103 (21.4%) initiated 
injection drug use. In a multivariable analysis, ≥ daily cannabis use was associated with 
slower rates of injection initiation (Adjusted Relative Hazard [ARH]: 0.66, 95% 
Confidence Interval [CI]: 0.45 – 0.98; p = 0.038). Subanalyses revealed that cannabis use 
was negatively associated with initiation of injection stimulants but not initiation of 
injection opioids.  
 
Discussion and Conclusions: Given the expansion of cannabis legalization throughout 
North America, it is encouraging that cannabis use was associated with slower time to 
initiation of injection drug use in this cohort. This finding challenges the view of cannabis 
as a gateway substance that precipitates the progression to using harder and more 
addictive drugs. 
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INTRODUCTION 
Injection drug use is an important risk factor for numerous adverse medical, social 
and legal outcomes, including HIV and hepatitis C acquisition and transmission, 
accidental fatal overdose, stigmatization and criminalization (1-3). Among illicit drug 
users, street-involved youth are at elevated risk to initiate injection drug use, which can 
be partially attributed to increased exposure to drug market activity and the age-linked 
stress associated with changing economic responsibilities and social roles that occur in 
this developmental period (4, 5). Previous studies have found the average age of injection 
initiation to be between 19 to 23 years (6, 7). Once youth initiate injecting, the majority 
have been found to quickly progress to regular injecting and experience greater drug 
related harm than older and more established people who use injection drugs (PWID) (8-
10). Specifically, young and recently initiated PWID are more likely to engage in high-
risk drug use practices such as needle sharing and binging (11, 12). As a result, young 
PWID display an increased risk of infectious disease transmission and overdose. Indeed, 
drug injection is an independent predictor of mortality among this population (9, 13-15). 
Risk factors for injection initiation include both structural factors, such as 
homelessness, unemployment and inability to access addiction treatment, as well as 
several individual-level exposures (16-19). For example, experiencing childhood trauma 
and specific drug use patterns, such as binging and polysubstance use, have been 
identified as predictors of injection initiation among at-risk youth (17-19). Additional 
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evidence indicates that the use of specific drugs including crack, powder cocaine, crystal 
methamphetamine have been linked to greater risks of injection initiation (20-22).  
The so-called gateway hypothesis, or the belief that certain forms of drug use 
promote progression to using ‘harder’ illicit drugs, has been the subject of much debate 
(23-26). Supporters of this theory suggest that substance use escalates from tobacco and 
alcohol to cannabis, with cannabis use facilitating the transition from licit substances to 
illicit drugs such as cocaine and heroin (24, 27). The three specific assertions of the 
gateway hypothesis are: 1) that few individuals use so-called hard drugs (e.g., heroin and 
cocaine) without initially experimenting with gateway substances such as cannabis and 
tobacco; 2) that drugs earlier in the sequence increase the risk of more serious substance 
use; 3) that the relationship between earlier gateway drugs and subsequent drug use is 
causal. Several epidemiological studies have supported the gateway sequence, including 
a 25-year longitudinal study of adolescents, which have reported that cannabis use was 
significantly associated with the use of other illicit drugs and illicit drug abuse (23, 28). 
Despite this evidence, many authors contend that this progression may be attributed to 
psychosocial, genetic and environmental determinants of drug use rather than causal 
effects of so-called gateway substances (23, 25, 26, 28, 29). Detailed examination of 
proposed gateway substances, particularly cannabis, is needed owing to the 
liberalization of cannabis policies in many settings in the Americas. Further, cannabis 
remains the most-frequently used illicit substance globally and the possible health-
related benefits and potential harms, including gateway effects, associated with cannabis 
use will be important to inform future regulation systems and both clinical and public 
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health practice (1). Although a wealth of studies have investigated the gateway 
hypothesis, the impact of so-called gateway drugs on the initiation of high-risk drug use 
behaviours, such as injecting, has not been fully evaluated. Given the high risk of 
injection-related harm among recently-initiated young injectors, as well as intense 
scrutiny of the possible impacts of cannabis on youth health in general, we sought to 
examine the impact of frequent cannabis use on rates of injection initiation among a 
prospective cohort of at-risk youth and young adults in Vancouver, Canada between 
September 2005 and May 2015 (9, 13-15, 32). To build on the existing research in this area, 
we also conducted subanalyses to examine the distinct of effects of cannabis use on both 
stimulant and opioid injecting. 
METHODS 
The data for this investigation were collected from the At-Risk Youth Study 
(ARYS) in Vancouver, Canada. This ongoing open prospective cohort was established in 
2005 and has been described in detail previously (33). Briefly, recruitment was performed 
through snowball sampling and extensive street outreach. Participants were eligible for 
enrolment if they were aged 14-26 years at the time of recruitment, had used illicit drugs 
(other than or in addition to cannabis) in the past 30 days and provided written informed 
consent. Previous studies of this cohort have reported a high prevalence of non-injection 
(cocaine: 49%, heroin: 16%, cannabis: 98%) and injection drug use (40%) (34). Data related 
to drug use behaviours, including injection drug use, was collected through an 
interviewer-administered questionnaire at baseline and semi-annually over follow-up. 
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At each study visit participants were remunerated $30 CAD to compensate for their time. 
The University of British Columbia’s Research Ethics Board has approved the ARYS 
study.  
In this study, we included all participants who were injection-naïve at baseline 
and completed at least one follow-up visit over the study period (September 2005 to May 
2015). The primary outcome of interest was the first report of any injection drug use. We 
defined the date of initiation as the midpoint between the last report of non-injection drug 
use and the first report of using a needle to inject drugs. The primary explanatory variable 
of interest was daily cannabis use in the last six months. Sociodemographic and drug use 
variables with the potential to confound the association between cannabis use and 
injection initiation were also included in the analysis. These variables included gender 
(non-male vs. male), age (per year older), ethnicity (white vs. other), non-injection cocaine 
use (yes vs. no), crack smoking (yes vs. no), non-injection crystal methamphetamine use 
(yes vs. no) and non-injection heroin use (yes vs. no). All drug use variables were treated 
as time-updated covariates based on semi-annual follow-up visits.  
The relationship between cannabis use and injection initiation was first assessed 
by calculating the incidence density of injection initiation using a Poisson model. The 
cumulative hazard of injection initiation from the time of study enrollment stratified by 
cannabis use was calculated using Kaplan-Meier methods. After estimating the 
unadjusted relative hazards and 95% confidence intervals for factors associated with 
injection initiation, an a priori multivariate model building protocol was applied to an 
extended Cox regression model. As a first step, a full multivariable including all variables 
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was constructed. The final model was developed by removing one covariate at a time 
from the full model that produced the smallest relative change in the cannabis use 
coefficient. This process was repeated in a manual stepwise manner until the minimum 
change in the cannabis use coefficient exceeded five percent. The purpose of this strategy 
is to retain covariates with a greater relative impact on the association between the 
primary explanatory variable and the outcome (35). A sub-analysis was also conducted 
to compare the impact of cannabis use on the initiation of injection opiates and the 
initiation of injection stimulants. Since the amount of missing data for the predictor 
variables was very low (0.17-0.51%), these values were excluded from the analysis. For 
the outcome of injection initiation, 67.3% of the participants only missed one follow-up 
visit and since we used time-updated covariates the values for the missing follow-up 
visits were imputed using the next most recent follow-up information. All statistical 
analyses were performed using SAS software version 9.3 (SAS, Cary, NC, USA) and all 
tests of significance were two-sided. 
RESULTS 
A total of 1215 street-involved youth enrolled in the ARYS cohort during the study 
period, of whom 684 (56%) were injection-naïve at the time of recruitment. During the 
study period, the average yearly loss to follow-up rate among these participants was 
2.75%. By the end of study period, a total of 481 youth who were injection-naïve at 
baseline completed at least one follow-up visit and were therefore eligible for the current 
analysis. The excluded participants did not differ significantly from the eligible 
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participants in terms of gender (p = 0.784), but they were more likely to be Caucasian (p 
= 0.001) and older in age (p-value = 0.001). Among the 481 participants included in the 
current study, the median observation time per participant was 21.9 months 
(interquartile range [IQR] = 12.2–43.2) and participants completed a median of 4 study 
visits (IQR = 2-6). The median time between study visits was 6.2 months (IQR: 5.7–8.0). 
At baseline, the median age of the participants was 21.5 (IQR = 19.5–23.2) years, 
333 (69.2%) were male, and 228 (47.4%) participants reported at least daily cannabis use 
(Table 1). During the study period, 103 (21.4%) participants reported initiating injection 
drug use, resulting in an incidence density of 8.3 events per 100 person years (95% 
Confidence Interval [CI]: 6.8–10.1). From study enrolment, the median time to injection 
initiation was 13.0 months (IQR: 4.0 – 27.7). The cumulative incidence rate was not 
significantly different among those who reported daily cannabis use at baseline 
compared to those who did not (log-rank p = 0.521). The proportion of baseline daily 
cannabis users who initiated injection drug use over follow-up was 48.5% compared to 
49.5% among those who did not report daily cannabis use at baseline.  
The unadjusted and adjusted relative hazards (ARH) of injection initiation are 
presented in Table 2. At least daily cannabis use (ARH: 0.66, 95% CI: 0.45 – 0.98; p = 0.038) 
was protective against injection initiation in the adjusted analysis. Other drug use 
variables associated with injection initiation included crack smoking (ARH: 2.53, 95% CI: 
1.69 – 3.77; p < 0.001) and crystal methamphetamine use (ARH: 3.66, 95% CI: 2.46 – 5.46; 
p < 0.001). A sub-analysis revealed that at least daily cannabis use was protective against 
the initiation of stimulant injecting (RH: 0.55, 95% CI: 0.33 – 0.92; p = 0.021), but the 
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association was not significant for initiation of opioid injecting (RH: 0.71, 95% CI: 0.44 – 
1.15; p = 0.166).  
DISCUSSION 
 In the present study, we observed a high rate of injection initiation among at-risk 
street-involved youth. Our results indicate that periods of frequent cannabis use were 
associated with slower rates of initiation: daily cannabis use was associated with a 34% 
decrease in the hazard rate of injection initiation. Sub-analyses revealed that this 
association remained was mainly driven by protecting against initiation of stimulant 
injection. No association between frequent cannabis use and opioid injection initiation 
was found. The decreased rate of injection initiation among frequent cannabis users 
challenges the claim of the gateway hypothesis that there is a causal link between 
cannabis use and initiation of subsequent so-called hard drug use.  
To our knowledge, only two studies have previously analyzed how cannabis use 
influences injection initiation among youth and young adults and these have reported 
conflicting results (22, 36). The first study was conducted in Baltimore, Maryland and 
found that cannabis use in the previous two years was positively associated with injection 
initiation (22).  Conversely, the second study found that among youth in Vancouver, 
Canada, cannabis use was associated with a decreased the risk of injection initiation (36). 
To explain this association, the authors speculate that cannabis users may represent a 
distinct subpopulation of young drug users who are uninterested in injection drug use 
based on the risk associated with injecting (36). Qualitative evidence from street youth 
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living in Montreal also indicate that certain groups avoid the use of ‘hard’ drugs, 
including cocaine and heroin, due to concerns about addiction, dependence and the risk 
of these drugs interfering with life goals (37). It is possible that a portion of the cannabis 
users in the ARYS cohort may reflect this characterization and seek out ‘softer’ drugs that 
are assumed to carry less risk of dependence (36). It is also important to acknowledge 
that cannabis use was defined as at least daily use in this study and less frequent cannabis 
use may not have the same impact on injection initiation.  
Although previous studies suggest that cannabis use is a high-risk behaviour that 
increases the risk of using other illicit drugs, it is encouraging that cannabis use did not 
increase the risk of injection initiation in this study. There is evidence to suggest that the 
impact of cannabis use on subsequent drug use behaviours may be moderated by 
additional exposures including environmental, psychosocial and genetic risk factors (25, 
38, 39). An analysis of nationally representative data from 17 countries (N>85,000) 
demonstrated that the association between cannabis use and subsequent illicit drug use 
was weaker in countries with higher rates of cannabis use, suggesting that drug use 
progressions may be moderated by drug prevalence and social acceptability of certain 
substances (38, 40). This pattern is believed to reflect differences in social norms, whereby 
use of less accessible drugs reflects a marker of ‘deviance’ more so than highly prevalent 
substances (40). These studies suggest that drug prevalence may moderate the association 
between use of a specific substance, such as cannabis, and more extreme subsequent drug 
use patterns such as injecting (40). In line with this theory, data from Statistics Canada 
revealed that the prevalence of past year cannabis use among a household population 
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aged 15 years and older in Vancouver (14.3%) is second only to Nova Scotia (15.7%) 
within Canada. Therefore cannabis use in this setting may be less likely to be regarded as 
a deviant behaviour, and in turn this may reduce the risk of progressing to more severe 
drug use (41). In the Netherlands, where cannabis use is highly prevalent, cannabis users 
are far less likely to initiate use of other illicit substances compared to the United States 
where cannabis use is less common (38). Twin and adoption studies have also indicated 
that drug use behaviours across substances may have common genetic influences that 
increase disinhibited drug use behaviours (39, 42, 43). These findings have led some 
authors to contend that the gateway sequence is a ‘progression of convenience’ that 
reflects drug accessibility, drug prevalence, individual predisposition and social 
acceptability of cannabis use, rather than a causal relationship between cannabis use and 
successive drug use (39, 42, 44). Cannabis may precede ‘harder’ drug use since it is more 
socially accepted, more common and represents a less extreme deviant behaviour 
compared to using other substances such as those that are commonly injected (42, 44).  
There is some biological plausibility for our finding that cannabis was associated 
with slower rates of initiation of injection stimulants. The two primary cannabinoids in 
cannabis, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have been shown to 
reduce measures of cocaine-induced cravings in rat models (45). These findings suggest 
that cannabis use may have beneficial effects by reducing intensity of stimulant use or 
reducing drug cravings associated with stimulant use.  However, caution should be 
exercised when applying findings from rodent models to humans, and this was the first 
study to report this association. It should also be noted that the concentration of CBD in 
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confiscated cannabis has remained low, although the concentration does vary based on 
region, season, quality and type of cannabis product (46, 47). Our findings, along with 
the absence of any pharmacotherapies for the treatment of stimulant use disorders, lends 
further support to recent calls for experimental trials in humans to investigate the 
therapeutic potential of cannabinoids for crack-cocaine use (48). While we did not 
observe a significant association between at least daily cannabis use and initiation of 
opioid injecting, there is evidence supporting cannabis use to reduce drug craving among 
heroin users (49, 50). Two pilot trials in humans demonstrated that single doses of 400 or 
800 mg of CBD over three consecutive days effectively decreased cue-induced craving, 
general craving and anxiety among heroin-dependent users that persisted for up to seven 
days (49, 50). Based on this preliminary evidence, the potential role of cannabinoids for 
the treatment of stimulant and opioid use disorder warrants further investigation.   
 Strengths of this study include the prospective repeated-measures design. This 
approach permitted the analysis of multiple independent risk factors for injection 
initiation that were time-updated during a nine year and eight month study period. This 
study also has limitations. Since ARYS represents a high-risk population of street-
involved youth and is not a random sample, these findings may not be generalizable to 
non-marginalized young people who use drugs from the general population. Although 
the reliability and validity of self-reported drug use measures has been demonstrated 
previously, socially desirable reporting of stigmatized and criminalized behaviours, and 
recall error remain concerns. We were also unable to assess the age of initiation for 
cannabis use and other illicit substances, which may have an important influence on the 
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associations we identified. Although the amount of missing data in this analysis was low, 
we acknowledge that the imputation for missing values may have influenced the results. 
The observational study design also creates the potential for residual confounding to 
influence the association between cannabis use and injection initiation. 
In summary, we prospectively analyzed injection initiation among 481 
participants in a longitudinal cohort of street-involved youth in Vancouver, Canada and 
found that frequent cannabis use was negatively associated with injection initiation. Sub-
analyses revealed that this effect was restricted to the initiation of stimulant injecting and 
there was no significant effect of cannabis use on the initiation of opioid injecting. Given 
the disproportionate harm experienced by youth who inject drugs, it is encouraging that 
cannabis use did not increase the risk of injection initiation in a setting with a high 
prevalence of cannabis use (41). With the legalization of cannabis use continuing to 
expand throughout North America and intense debates over the possible impacts of 
cannabis on youth health, future studies analyzing the impact of cannabis use on high-
risk drug behaviours are needed to address other potential concerns surrounding these 
policies.  
 
  
Cannabis Use and Injection Initiation 
 
 
14 
Acknowledgments: 
The authors thank the study participants for their contribution to the research, as well 
as current and past researchers and staff. We would specifically like to thank Cody 
Callon, Jennifer Matthews, Deborah Graham, Peter Vann, Steve Kain, Tricia 
Collingham, Kristie Starr, Ana Prado, and Carmen Rock for their research and 
administrative support. The study was supported by the US National Institutes of 
Health (U01DA038886) and the Canadian Institutes of Health Research (MOP–286532). 
This research was undertaken, in part, thanks to funding from the Canada Research 
Chairs program through a Tier 1 Canada Research Chair in Inner City Medicine which 
supports Dr. Evan Wood. Hudson Reddon is supported by an Ontario Graduate 
Scholarship. Dr. Kora DeBeck is supported by a MSFHR / St. Paul’s Hospital 
Foundation–Providence Health Care Career Scholar Award and a Canadian Institutes 
of Health Research New Investigator Award. Dr. M-J Milloy is supported in part by the 
United States National Institutes of Health (R01-DA021525), a New Investigator Award 
from the Canadian Institutes of Health Research and a Scholar Award from the Michael 
Smith Foundation of Health Research. His institution has received an unstructured gift 
to support his research from NG Biomed, Ltd., a private firm applying for a government 
license to produce medical cannabis. MES is supported by a Michael Smith Foundation 
for Health Research post-doctoral fellowship award and a Canada Addiction Medicine 
Research Fellowship (NIDA R25-DA037756).  
  
Cannabis Use and Injection Initiation 
 
15 
 
References 
1. DeBeck K, Shannon K, Wood E, Li K, Montaner J, Kerr T. Income generating 
activities of people who inject drugs. Drug Alcohol Depend. 2007;91(1):50-6. 
2. Marshall BD, Kerr T, Shoveller JA, Patterson TL, Buxton JA, Wood E. 
Homelessness and unstable housing associated with an increased risk of HIV and STI 
transmission among street-involved youth. Health Place. 2009;15(3):753-60. 
3. Miller CL, Kerr T, Fischer B, Zhang R, Wood E. Methamphetamine injection 
independently predicts hepatitis C infection among street-involved youth in a Canadian 
setting. J Adolesc Health. 2009;44(3):302-4. 
4. Fuller CM, Vlahov D, Ompad DC, Shah N, Arria A, Strathdee SA. High-risk 
behaviors associated with transition from illicit non-injection to injection drug use 
among adolescent and young adult drug users: a case-control study. Drug Alcohol 
Depend. 2002;66(2):189-98. 
5. Van Gundy K, Rebellon CJ. A Life-course Perspective on the "Gateway 
Hypothesis". Journal of health and social behavior. 2010;51(3):244-59. 
6. Fuller CM, Vlahov D, Arria AM, Ompad DC, Garfein R, Strathdee SA. Factors 
associated with adolescent initiation of injection drug use. Public health reports. 
2001;116 Suppl 1:136-45. 
7. Ompad DC, Ikeda RM, Shah N, Fuller CM, Bailey S, Morse E, et al. Childhood 
sexual abuse and age at initiation of injection drug use. American journal of public 
health. 2005;95(4):703-9. 
8. Debeck K, Kerr T, Marshall BD, Simo A, Montaner J, Wood E. Risk factors for 
progression to regular injection drug use among street-involved youth in a Canadian 
setting. Drug Alcohol Depend. 2013;133(2):468-72. 
9. Roy E, Haley N, Leclerc P, Sochanski B, Boudreau JF, Boivin JF. Mortality in a 
cohort of street youth in Montreal. Jama. 2004;292(5):569-74. 
10. Marshall BD, Kerr T, Qi J, Montaner JS, Wood E. Public injecting and HIV risk 
behaviour among street-involved youth. Drug Alcohol Depend. 2010;110(3):254-8. 
11. Lloyd-Smith E, Kerr, T., Zhang, R., Montaner, JSG., Wood, E. High prevalence of 
syringe sharing among street involved youth. Addict Res Theory. 2008;16:353–8. 
12. Mitra G, Wood E, Nguyen P, Kerr T, DeBeck K. Drug use patterns predict risk of 
non-fatal overdose among street-involved youth in a Canadian setting. Drug Alcohol 
Depend. 2015;153:135-9. 
  
16 
13. Fennema JS, Van Ameijden EJ, Van Den Hoek A, Coutinho RA. Young and 
recent-onset injecting drug users are at higher risk for HIV. Addiction. 1997;92(11):1457-
65. 
14. Seal KH, Kral AH, Gee L, Moore LD, Bluthenthal RN, Lorvick J, et al. Predictors 
and prevention of nonfatal overdose among street-recruited injection heroin users in the 
San Francisco Bay Area, 1998-1999. Am J Public Health. 2001;91(11):1842-6. 
15. Montain J, Ti L, Hayashi K, Nguyen P, Wood E, Kerr T. Impact of length of 
injecting career on HIV incidence among people who inject drugs. Addict Behav. 
2016;58:90-4. 
16. DeBeck K, Kerr T, Nolan S, Dong H, Montaner J, Wood E. Inability to access 
addiction treatment predicts injection initiation among street-involved youth in a 
Canadian setting. Subst Abuse Treat Prev Policy. 2016;11:1. 
17. Trenz RC, Scherer M, Harrell P, Zur J, Sinha A, Latimer W. Early onset of drug 
and polysubstance use as predictors of injection drug use among adult drug users. 
Addict Behav. 2012;37(4):367-72. 
18. Miller CL, Strathdee SA, Kerr T, Li K, Wood E. Factors associated with early 
adolescent initiation into injection drug use: implications for intervention programs. J 
Adolesc Health. 2006;38(4):462-4. 
19. Hadland SE, Werb D, Kerr T, Fu E, Wang H, Montaner JS, et al. Childhood 
sexual abuse and risk for initiating injection drug use: a prospective cohort study. Prev 
Med. 2012;55(5):500-4. 
20. Werb D, Kerr T, Buxton J, Shoveller J, Richardson C, Montaner J, et al. Crystal 
methamphetamine and initiation of injection drug use among street-involved youth in a 
Canadian setting. Cmaj. 2013;185(18):1569-75. 
21. Roy E, Haley N, Leclerc P, Cedras L, Blais L, Boivin JF. Drug injection among 
street youths in Montreal: predictors of initiation. J Urban Health. 2003;80(1):92-105. 
22. Fuller CM, Vlahov D, Arria AM, Ompad DC, Garfein R, Strathdee SA. Factors 
associated with adolescent initiation of injection drug use. Public Health Rep. 2001;116 
Suppl 1:136-45. 
23. Kandel D. Stages in adolescent involvement in drug use. Science. 
1975;190(4217):912-4. 
24. Kandel DB, Yamaguchi K, Klein LC. Testing the Gateway Hypothesis. Addiction. 
2006;101(4):470-2; discussion 4-6. 
  
17 
25. Mayet A, Legleye S, Beck F, Falissard B, Chau N. The Gateway Hypothesis, 
Common Liability to Addictions or the Route of Administration Model A Modelling 
Process Linking the Three Theories. Eur Addict Res. 2016;22(2):107-17. 
26. Kleinig J. Ready for Retirement: The Gateway Drug Hypothesis. Subst Use 
Misuse. 2015;50(8-9):971-5. 
27. Kandel DB. Examining the gateway hypothesis: Stages and pathways of drug 
involvement. In D. B. Kan- del (Ed.), Stages and pathways of drug involvement: 
Examining the gateway hypothesis ( pp. 3–18). New York: Cambridge University Press; 
2002. 
28. Kleinig J. Ready for Retirement: The Gateway Drug Hypothesis. Substance use & 
misuse. 2015;50(8-9):971-5. 
29. Mayet A, Legleye S, Beck F, Falissard B, Chau N. The Gateway Hypothesis, 
Common Liability to Addictions or the Route of Administration Model A Modelling 
Process Linking the Three Theories. European addiction research. 2016;22(2):107-17. 
30. Cleveland HH, Wiebe RP. Understanding the association between adolescent 
marijuana use and later serious drug use: gateway effect or developmental trajectory? 
Development and psychopathology. 2008;20(2):615-32. 
31. United Nations Office on Drugs and Crime. New York: World drug report; 2014. 
32. Fischer B, Rehm J, Crepault JF. Realistically furthering the goals of public health 
by cannabis legalization with strict regulation: Response to Kalant. Int J Drug Policy. 
2016. 
33. Wood E, Stoltz JA, Montaner JS, Kerr T. Evaluating methamphetamine use and 
risks of injection initiation among street youth: the ARYS study. Harm Reduct J. 
2006;3:18. 
34. Werb D, Kerr T, Buxton J, Shoveller J, Richardson C, Montaner J, et al. Crystal 
methamphetamine and initiation of injection drug use among street-involved youth in a 
Canadian setting. CMAJ : Canadian Medical Association journal = journal de 
l'Association medicale canadienne. 2013;185(18):1569-75. 
35. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. 
Am J Epidemiol. 1993;138(11):923-36. 
36. Hadland SE, Kerr T, Marshall BD, Small W, Lai C, Montaner JS, et al. Non-
injection drug use patterns and history of injection among street youth. Eur Addict Res. 
2010;16(2):91-8. 
  
18 
37. Roy E, Nonn E, Haley N. Transition to injection drug use among street youth--a 
qualitative analysis. Drug Alcohol Depend. 2008;94(1-3):19-29. 
38. Degenhardt L, Dierker L, Chiu WT, Medina-Mora ME, Neumark Y, Sampson N, 
et al. Evaluating the drug use "gateway" theory using cross-national data: consistency 
and associations of the order of initiation of drug use among participants in the WHO 
World Mental Health Surveys. Drug Alcohol Depend. 2010;108(1-2):84-97. 
39. Cleveland HH, Wiebe RP. Understanding the association between adolescent 
marijuana use and later serious drug use: gateway effect or developmental trajectory? 
Dev Psychopathol. 2008;20(2):615-32. 
40. Breslau N, Novak SP, Kessler RC. Psychiatric disorders and stages of smoking. 
Biol Psychiatry. 2004;55(1):69-76. 
41. Rotermann M, Langlois, K. Prevalence and correlates of marijuana use in 
Canada, 2012. Health Rep. 2015;26(4):10-5. 
42. Golub A, & Johnson, B. D. The misuse of the“Gateway Theory” in US policy on 
drug abuse control: A secondary analysis of the muddled deduction. International 
Journal of Drug Policy. 2002;13:5-19. 
43. Agrawal A, Lynskey MT. Cannabis controversies: how genetics can inform the 
study of comorbidity. Addiction. 2014;109(3):360-70. 
44. Wagner FA, Anthony JC. Into the world of illegal drug use: exposure 
opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and 
cocaine. American journal of epidemiology. 2002;155(10):918-25. 
45. Parker LA, Burton P, Sorge RE, Yakiwchuk C, Mechoulam R. Effect of low doses 
of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced 
and amphetamine-induced conditioned place preference learning in rats. 
Psychopharmacology (Berl). 2004;175(3):360-6. 
46. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in 
Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the 
United States. Biological psychiatry. 2016;79(7):613-9. 
47. Swift W, Wong A, Li KM, Arnold JC, McGregor IS. Analysis of cannabis seizures 
in NSW, Australia: cannabis potency and cannabinoid profile. PloS one. 
2013;8(7):e70052. 
48. Fischer B, Kuganesan S, Gallassi A, Malcher-Lopes R, van den Brink W, Wood E. 
Addressing the stimulant treatment gap: A call to investigate the therapeutic benefits 
potential of cannabinoids for crack-cocaine use. Int J Drug Policy. 2015;26(12):1177-82. 
  
19 
49. Manini AF, Yiannoulos G, Bergamaschi MM, Hernandez S, Olmedo R, Barnes AJ, 
et al. Safety and pharmacokinetics of oral cannabidiol when administered 
concomitantly with intravenous fentanyl in humans. J Addict Med. 2015;9(3):204-10. 
50. Hurd YL, Yoon M, Manini AF, Hernandez S, Olmedo R, Ostman M, et al. Early 
Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse 
Takes Initial Center Stage. Neurotherapeutics. 2015;12(4):807-15. 
 
 
